1CABMS, Lecturer, College of Medicine, University of Thi-qar, Republic of Iraq
2FICMS, Urologist, Al Hussien Teaching Hospital, MOH, Republic of Iraq
*Corresponding author: Ali Abdulbaqi Ali Ismael Email. ali_abdulbaqi@yahoo.com
Online published on 9 January, 2019.
Overactive bladder (OAB) is a condition characterized by urinary urgency, usually accompanied by frequency and nocturia, with or without urge urinary incontinence. this prospective study aimed to discuss the pharmacotheraputic aspects of mirabegrone in treatment of overactive bladder. Hence a total of 71 patients with diagnosis of overactive bladder were enrolled and randomly assigned into two groups; mirabegron 50 and B who received 50 and 100 mg mirabegrone, respectively and patients were followed for 8 weeks.
Only 66 patients completed the study. Mirabegron at doses of 50 and 100 mg once daily demonstrated improvement from baseline to final visit in reducing the mean number of micturitions per 24 hours which increased with mirabegron dose but no significant improvement between mirabegron groups. There's significant improvement between mirabegron groups in mean baseline to end-of-treatment for urgency episodes (p<0.001) and level of urgency incontinence (p<0.01). In conclusion, Mirabegron at doses of 50 and 100 mg once-daily over 8 weeks demonstrated satisfactory balance between efficacy and tolerability in Overactive Bladder patients.
Overactive Bladder, Mirabegron, urinary urgency, nocturia, urinary incontinence
